To address the high failure rate of certain implantable devices, Senseer Health develops wirelessly-controlled, implantable micro sensors technologies that can be combined with devices such as catheters, shunts, or grafts in order to make these devices smart. Our technology enables remote tracking of devices status, thus enabling alerting and timely intervention before a complete device failure occurs. Our team's initial focus is on hydrocephalus, a severe neurological disease that affects over 1M people in the US alone, including ~600,000 pediatric patients. The most common treatment for hydrocephalus is the surgical insertion of a drainage system, called a shunt, to drain excess cerebrospinal fluid (CSF) from the patient's brain. These devices, however, fail at an extremely high rate, oftentimes exceeding 40% within the first year of implantation, rapidly leading to permanent brain damage, if not being addressed in time.

Leading life sciences strategy projects with focus on the pharmaceutical, biotechnology, and medical device industries, combining industry, scientific and market research knowledge with specialized expertise in market assessment, analytics, and developing actionable commercialization strategies.

• Developed and maintained new relationships with KOLs, physicians and medical device industry leaders, in order to a) identify unmet clinical needs and opportunities, and b) build long-term relationships/partnerships with industry• Developed novel medical device concepts, prototypes and IP, and engaged industry in product development• Co-led a graduate level multi-disciplinary course on medical device design and innovation.

Laboratory Operations• Led scientific development, including sourcing, evaluating, and executing collaborations• Oversaw all scientific development, business planning, including new product feasibility and market research• Established collaboration with the USC Norris Cancer Center, Genetic EpidemiologyRegulatory Affairs• Served as Principle Investigator on three IRB protocols• Led all research-related regulatory aspects while serving as main point-of-contact for the Institutional Review Board (IRB)• Set-up and instructed clinical sites for the collection of patient biospecimens and health recordsMarketing• Directed and managed 10 scientific editors. Edited and distributed content via HootSuite on LinkedIn, Facebook and Twitter• Developed email marketing strategy and generated leads through email campaigns via NetResults and Amazon SES• Represented Sanguine at conferences and vendor shows

Assessed market opportunities and conducted technology feasibility analysis for a novel reversible temperature-dependent wound closure system, leading to an initial $2M investment round by the Alfred Mann Institute.

• Evaluated and researched pharmaceutical market in the field of ulcerative colitis in order to revise the firm’s business plan, and to analyze potential competitors.• Analyzed pharmaceutical market with regards to therapeutic drugs against non-alcoholic steatohepatitis. • Managed and built relationships to scientists, investors and clinical research associates to promote new drug development.

• Sourced and evaluated deals for a $100M Venture Capital fund that invests in early-stage semiconductor, energy, and life-science companies.• Organized VC/entrepreneur meetings• Increased firm’s network, leading to potential future co-investment strategies.

• Studied gene expression induced by chronic antidepressant treatment in order to test the hypothesis that antidepressant drugs regulate specific genes responsible for depression, and showed that these drugs activate certain signaling pathways. • Showed that treatment with certain drugs led to an activation of the Wnt/wg signaling pathway in the hypothalamus, followed by an accumulation of beta-catenin, a transcription factor that usually plays an important role during embryogenesis.